# US 2023/0405086 A1 · Compositions and methods for preventing, detecting, and treating inflammatory bowel disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405086 A1
- Document ID: US20230405086A1
- Status: Published application
- Kind: A1
- Application number: 17/997,616
- Filed: 2021-04-30
- Published: 2023-12-21
- Earliest claimed: 2020-05-01
- Assignees: Icahn School of Medicine at Mount Sinai; The Governing Council of the University of Toronto
- Applicants: Icahn School of Medicine At Mount Sinai; The Governing Council of the University of Toronto
- Inventors: Sacha GNJATIC; Arthur MORTHA; Jean-Frederic COLOMBEL; Romain REMARK; Miriam MERAD
- Web page: https://patentgrep.com/patent/US20230405086A1

## CPC

- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/12: Antidiarrhoeals
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6863: {Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors}
- G01N 2333/535: Granulocyte CSF; Granulocyte-macrophage CSF
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to a composition comprising a post-translationally modified Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) protein. The disclosure further relates to methods of preventing or treating Crohn's Disease and/or a condition resulting from Crohn's Disease in a subject. The disclosure further relates to methods for diagnosing and/or predicting severity of and/or treating Crohn's Disease in a subject. Also disclosed are methods for diagnosing inflammatory bowel disease in a subject and methods for diagnosing a pre-disease state of Crohn's Disease in a subject.

## Claims

### Claim at position 1

1-69. (canceled)

### Claim 70

A method of preventing or treating one or both of an inflammatory bowel disease (IBD) and a condition resulting from the IBD in a subject comprising:
selecting a subject having or at risk of having the IBD and
administering a Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) protein to the selected subject under conditions effective to prevent or treat one or both of the IBD and a condition resulting from the IBD in the subject.

### Claim 71 (depends on 70)

The method of claim 70, wherein the GM-CSF protein is glycosylated.

### Claim 72 (depends on 70)

The method of claim 70, wherein the GM-CSF protein is not glycosylated.

### Claim 73 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at S22.

### Claim 74 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at S24.

### Claim 75 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at T27.

### Claim 76 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at S26.

### Claim 77 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at N44.

### Claim 78 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an amino acid substitution at N54.

### Claim 79 (depends on 70)

The method of claim 70, wherein the GM-CSF comprises an alanine substitution at one or more of S22, S24, T27, S26, N44, and N54.

### Claim 80 (depends on 70)

The method of claim 70, wherein the administering comprises inhalation, intranasal instillation, topically, transdermally, intradermally, parenterally, subcutaneously, intravenous injection, intra-arterial injection, intramuscular injection, intrapleurally, intraperitoneally, intrathecally, or application to a mucous membrane.

### Claim 81 (depends on 70)

The method of claim 70, wherein the administering comprises administering a pharmaceutical composition, wherein the pharmaceutical composition comprises the GM-CSF and a pharmaceutically acceptable carrier.

### Claim 82 (depends on 70)

The method of claim 70, wherein the IBD is Crohn's disease.

### Claim 83 (depends on 70)

The method of claim 70, wherein the IBD is ulcerative colitis.

### Claim 84 (depends on 70)

The method of claim 70, further comprising administering to the subject one or more additional agent that prevents or treats the IBD and/or a condition resulting from the IBD, wherein the additional agent is selected from an antibiotic, an anti-inflammatory, or an immunosuppressant.

### Claim 85 (depends on 70)

The method of claim 70, wherein the selecting comprises detecting or having detected the presence of anti-GM-CSF autoantibodies in a sample from the subject.

### Claim 86 (depends on 85)

The method of claim 85, wherein the sample is selected from whole blood, serum, urine, and nasal excretion.

### Claim 87 (depends on 85)

The method of claim 85, wherein the GM-CSF comprises an amino acid substitution at one or more of S22, S24, T27, S26, N44, and N54.

### Claim 88 (depends on 85)

The method of claim 85, wherein the administering comprises administering a pharmaceutical composition, wherein the pharmaceutical composition comprises the GM-CSF and a pharmaceutically acceptable carrier.

### Claim 89 (depends on 70)

The method of claim 70, wherein the IBD is Crohn's disease or ulcerative colitis.
